本文選題：非小細胞肺癌 + Ventana免疫組化��； 參考：《廣西醫(yī)科大學》2017年碩士論文

【摘要】：目的:為豐富中國非小細胞肺癌患者ALK陽性數(shù)據(jù),及為篩選非小細胞細胞肺癌患者的ALK陽性患者及個體化治療提供依據(jù)。材料及方法:收集廣西醫(yī)科大學附屬腫瘤醫(yī)院從2014年12月至2016年6月行ALK Ventana免疫組織化學染色的且經(jīng)組織病理學明確診斷為非小細胞肺癌的患者532例,回顧性分析ALK融合基因陽性患者的臨床特征,數(shù)據(jù)采用SPSS17.0軟件進行統(tǒng)計分析,ALK陽性和陰性病人臨床特征組間比較采用卡方檢驗,校正采用連續(xù)校正X2檢驗及Fisher確切概率法。P0.05認為有統(tǒng)計學意義。結果:1、在532例非小細胞肺癌患者中,男性患者326例,女性患者206例;平均年齡為56.9歲,65歲患者410例,≥65歲患者122例;手術標本153例,淋巴結活檢標本43例,穿刺活檢小標本313例,細胞學23例;有吸煙史患者238例,無吸煙史294例。在532例非小細胞肺癌中,腺癌455例,鱗癌52例,腺鱗癌13例,其他類型12例;原發(fā)部位位于左肺有215例,右肺有301例,中央型肺癌有201例,周圍型肺癌有315例;TNM分期為Ⅰ期的病例有55例,Ⅱ期有27例,Ⅲ期有113例,Ⅳ期有324例;EGFR突變有132例,無EGFR突變有179例,EGFR突變率為42.4%。2、在532例非小細胞肺癌病例中,經(jīng)ALK Ventana免疫組織化學染色檢測,ALK陽性的有46例,陽性率為8.6%。3、在46例ALK融合基因陽性的患者中,分析其臨床特征構成比,多見于年齡65歲、女性、無吸煙史、原發(fā)部位為右肺或中央型、TNM分期為Ⅳ期的肺腺癌患者,且多不合并EGFR基因突變。4、在ALK陽性組與ALK陰性組的對比中,其臨床病理特征在年齡、性別、吸煙史、病理類型、原發(fā)部位為中央型或周圍型、是否合并EGFR突變方面,差別具有統(tǒng)計學意義(P0.05),在原發(fā)部位為左肺或右肺、TNM分期上,差別無統(tǒng)計學意義(P0.05)。結論:ALK融合基因多在女性、年齡65歲、無吸煙史、中央型、肺腺癌、不合并EGFR突變的患者中表達,其差異具有統(tǒng)計學意義。
[Abstract]:Objective: to enrich the ALK positive data of non-small cell lung cancer (NSCLC) patients in China and to provide evidence for screening ALK positive patients and individualized treatment for NSCLC patients. Materials and methods: a total of 532 patients with non-small cell lung cancer (NSCLC) diagnosed by histopathology from December 2014 to June 2016 in the affiliated Cancer Hospital of Guangxi Medical University were collected. The clinical features of patients with positive ALK fusion gene were analyzed retrospectively. The data were statistically analyzed by SPSS17.0 software in order to compare the clinical features of positive and negative patients with ALK by chi-square test. Continuous correction X 2 test and Fisher exact probability method. Results among 532 patients with non-small cell lung cancer, 326 were male, 206 were female, 410 were 56.9 years old or 65 years old, 122 were 鈮，

本文編號：1953861